CA2373128A1 - Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application - Google Patents
Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application Download PDFInfo
- Publication number
- CA2373128A1 CA2373128A1 CA002373128A CA2373128A CA2373128A1 CA 2373128 A1 CA2373128 A1 CA 2373128A1 CA 002373128 A CA002373128 A CA 002373128A CA 2373128 A CA2373128 A CA 2373128A CA 2373128 A1 CA2373128 A1 CA 2373128A1
- Authority
- CA
- Canada
- Prior art keywords
- tetrapeptide
- proposed
- substance
- glu
- asp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title abstract 5
- 230000002398 geroprotective effect Effects 0.000 title abstract 3
- 230000000144 pharmacologic effect Effects 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 abstract 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 abstract 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 abstract 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 abstract 1
- 206010063493 Premature ageing Diseases 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052744 lithium Inorganic materials 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 abstract 1
- 229910052749 magnesium Inorganic materials 0.000 abstract 1
- 239000011591 potassium Substances 0.000 abstract 1
- 229910052700 potassium Inorganic materials 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-O triethylammonium ion Chemical compound CC[NH+](CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-O 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Tetrapeptide L-alanyl-L-glutamyl-L-aspartyl-glycine of the general formula L-Ala-L-Glu-L-Asp-Gly is proposed as a biologically active compound with a geroprotective effect. The use of L-Ala-L-Glu-L-Asp-Gly tetrapeptide in medicine is proposed for preparing a substance displaying a geroprotective effect. There is proposed a pharmacological substance, which contains as its active base an effective amount of tetrapeptide of the formula L-alanyl-L-glutamyl-L-aspartyl-glycine (L-Ala-L-Glu-L-Asp-Gly) or its salts of the amino group (acetate, hydrochloride, oxalate) and of carboxyl groups (the salts of metals-Sodium, Potassium, Calcium, Lithium, Zinc, Magnesium, and also the salts of organic and inorganic cations-ammonium and triethylammonium). The substance is proposed for parenteral, intranasal, oral administration, and local application. With respect to the invention, the method of premature ageing prevention involves prophylactic and/or therapeutic administration to a patient of the pharmacological substance in doses of 0.01 to 100 µg/kg of body weight at least once a day for a period necessary for the achievement of a therapeutic effect.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU99108841 | 1999-05-11 | ||
| RU99108841/14A RU2157233C1 (en) | 1999-05-11 | 1999-05-11 | Tetrapeptide showing geroprotective activity, pharmacological agent based on thereof and method of its use |
| PCT/RU2000/000012 WO2000068255A2 (en) | 1999-05-11 | 2000-01-20 | Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2373128A1 true CA2373128A1 (en) | 2000-11-16 |
| CA2373128C CA2373128C (en) | 2007-03-13 |
Family
ID=20219149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002373128A Expired - Fee Related CA2373128C (en) | 1999-05-11 | 2000-01-20 | Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6727227B1 (en) |
| EP (1) | EP1179008B1 (en) |
| JP (1) | JP3902406B2 (en) |
| AT (1) | ATE321068T1 (en) |
| AU (1) | AU769847C (en) |
| CA (1) | CA2373128C (en) |
| DE (1) | DE60026826T2 (en) |
| ES (1) | ES2259998T3 (en) |
| IL (2) | IL146432A0 (en) |
| RU (1) | RU2157233C1 (en) |
| WO (1) | WO2000068255A2 (en) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8680059B2 (en) * | 1998-05-20 | 2014-03-25 | Biotempt B.V. | Oligopeptide acetate and formulations thereof |
| US6844315B2 (en) * | 1998-05-20 | 2005-01-18 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US20030220258A1 (en) | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of ischemic events |
| US7175679B2 (en) * | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
| US20040202645A1 (en) * | 2003-04-08 | 2004-10-14 | Khan Nisar Ahmed | Administration of gene-regulatory peptides |
| EP1138692A1 (en) * | 2000-03-29 | 2001-10-04 | Erasmus Universiteit Rotterdam | Fragments of human chorionic gonadotropin (hcg) as immunoregulator |
| US20050227925A1 (en) * | 2004-04-08 | 2005-10-13 | Robbert Benner | Compositions capable of reducing elevated blood urea concentration |
| US6921751B1 (en) * | 1998-05-20 | 2005-07-26 | Erasmus Universiteit Rotterdam | Immunoregulator |
| US7358330B2 (en) * | 2001-03-29 | 2008-04-15 | Biotempt B.V. | Immunoregulatory compositions |
| USRE43279E1 (en) | 2000-03-29 | 2012-03-27 | Biotemp B.V. | Compositions capable of reducing elevated blood urea concentration |
| EP1300418A1 (en) | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| US7576174B2 (en) * | 2000-03-29 | 2009-08-18 | Biotempt B.V. | Compositions capable of reducing elevated blood urea concentration |
| RU2161501C1 (en) * | 2000-06-29 | 2001-01-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Method of preparing peptides showing tissue-specific activity and pharmaceutical composition based on thereof |
| WO2002090380A1 (en) * | 2001-04-17 | 2002-11-14 | Sankt-Peterburgskaya Obschestvennaya Organizatsiya 'institut Bioregulyatsii I Gerontologii Czo Ramn' | Tetrapeptide stimulating the retinal function and the method of its application |
| US20080318871A1 (en) * | 2001-12-21 | 2008-12-25 | Khan Nisar A | Treatment of neurological disorders |
| US7501391B2 (en) | 2001-12-21 | 2009-03-10 | Biotempt B.V. | Treatment of transplant survival |
| US20030220261A1 (en) * | 2001-12-21 | 2003-11-27 | Khan Nisar Ahmed | Treatment of iatrogenic disease |
| US20030224995A1 (en) * | 2001-12-21 | 2003-12-04 | Khan Nisar Ahmed | Treatment of burns |
| US7786084B2 (en) * | 2001-12-21 | 2010-08-31 | Biotempt B.V. | Treatment of burns |
| US20040013661A1 (en) * | 2001-12-21 | 2004-01-22 | Gert Wensvoort | Stratification |
| US7560433B2 (en) * | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US20030220257A1 (en) * | 2001-12-21 | 2003-11-27 | Robbert Benner | Treatment of trauma |
| US20080242837A1 (en) * | 2001-12-21 | 2008-10-02 | Khan Nisar A | Peptide compositions |
| US7517529B2 (en) * | 2003-04-08 | 2009-04-14 | Biotempt B.V. | Treatment of type I diabetes |
| RU2257910C1 (en) * | 2003-12-25 | 2005-08-10 | Институт физиологически активных веществ Российской Академии Наук (ИФАВ РАН) | Vegetable extracts eliciting geriatric-protecting activity and agent based on thereof |
| RU2257909C1 (en) * | 2003-12-25 | 2005-08-10 | Институт физиологически активных веществ Российской Академии Наук (ИФАВ РАН) | Bilberry sprout concentrate and compositions based on thereof eliciting geriatric-protecting activity |
| US20090227505A1 (en) * | 2004-01-07 | 2009-09-10 | Biotempt B.V. | Methods and uses for protein breakdown products |
| RU2255757C1 (en) * | 2004-06-22 | 2005-07-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Peptide compound recovering function of respiratory organs |
| RU2255756C1 (en) * | 2004-06-22 | 2005-07-10 | Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" | Peptide compound recovering function of myocardium |
| RU2297215C2 (en) * | 2005-02-21 | 2007-04-20 | Государственное образовательное учреждение высшего профессионального образования "Рязанский государственный медицинский университет им. акад. И.П. Павлова" МЗ РФ | Antioxidant agent for cataract treatment |
| JP4846799B2 (en) * | 2005-07-05 | 2011-12-28 | バイオテンプト ベー．フェー． | Tumor treatment |
| EP1864692A1 (en) * | 2006-06-07 | 2007-12-12 | Biotempt B.V. | Use of peptides for the control of radiation injury |
| RU2304444C1 (en) * | 2006-05-23 | 2007-08-20 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Peptide possessing stress-protecting effect, pharmaceutical composition based on thereof and method for its using |
| RU2295970C1 (en) * | 2006-05-23 | 2007-03-27 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Peptide enhancing resistance of capillaries, pharmaceutical composition based on thereof and method for its using |
| RU2301678C1 (en) * | 2006-05-30 | 2007-06-27 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Peptide stimulating regeneration of central nervous system neurons, pharmaceutical composition based on thereof and method for its using |
| RU2301074C1 (en) * | 2006-05-30 | 2007-06-20 | Общество С Ограниченной Ответственностью "Сиа Пептайдс" | Peptide possessing immunogeroprotective effect, pharmaceutical composition based on thereof and method for its using |
| PT2120991E (en) * | 2007-02-12 | 2014-05-02 | Biotempt Bv | Treatment of trauma hemorrhage with short oligopeptides |
| RU2464816C1 (en) * | 2011-04-14 | 2012-10-27 | Общество с ограниченной ответственностью "Вилави" | Biologically active substances composition with geroprotective activity and method for complex correction of age-related changes of hormonal balance, epiphysis functions and antioxidant status involving said composition administration |
| WO2016190750A1 (en) * | 2015-05-22 | 2016-12-01 | The A2 Milk Company Limited | Beta-casein a2 and antioxidant capacity |
| CN115379847A (en) * | 2020-04-15 | 2022-11-22 | 拉托科公司 | Synthetic peptides for modulating metabotropic glutamate receptor 5 |
| KR102841388B1 (en) * | 2022-08-30 | 2025-08-01 | 주식회사 제이포셀 | Anti-aging cosmetic composition comprising anti-aging peptide and Astragalus extract |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH078273A (en) * | 1993-06-14 | 1995-01-13 | Kurabo Ind Ltd | Serum-free culture of adherent animal cells |
| JPH0851980A (en) * | 1994-08-11 | 1996-02-27 | Asahi Glass Co Ltd | Synthetic gene and method for producing peptide having cancer metastasis inhibitory activity using the same |
| RU2099078C1 (en) * | 1994-12-08 | 1997-12-20 | Акционерное общество закрытого типа "КОМКОН" | Agent showing antistress, stress-protecting, nootropic, antialcoholic, antinarcotic effect, methods of prophylaxis and treatment using thereof |
| RU2112512C1 (en) * | 1995-09-22 | 1998-06-10 | Иванов Евгений Васильевич | Biologically active food addition "glutapyron" showing anticarcinogenic and geroprotective effect |
| CA2307954C (en) * | 1997-04-03 | 2010-07-13 | California Institute Of Technology | Enzyme-medicated modification of fibrin for tissue engineering |
-
1999
- 1999-05-11 RU RU99108841/14A patent/RU2157233C1/en not_active IP Right Cessation
-
2000
- 2000-01-20 EP EP00905499A patent/EP1179008B1/en not_active Expired - Lifetime
- 2000-01-20 WO PCT/RU2000/000012 patent/WO2000068255A2/en not_active Ceased
- 2000-01-20 AU AU27034/00A patent/AU769847C/en not_active Ceased
- 2000-01-20 JP JP2000616229A patent/JP3902406B2/en not_active Expired - Fee Related
- 2000-01-20 ES ES00905499T patent/ES2259998T3/en not_active Expired - Lifetime
- 2000-01-20 IL IL14643200A patent/IL146432A0/en active IP Right Grant
- 2000-01-20 CA CA002373128A patent/CA2373128C/en not_active Expired - Fee Related
- 2000-01-20 US US09/959,852 patent/US6727227B1/en not_active Expired - Fee Related
- 2000-01-20 DE DE60026826T patent/DE60026826T2/en not_active Expired - Lifetime
- 2000-01-20 AT AT00905499T patent/ATE321068T1/en active
-
2001
- 2001-11-11 IL IL146432A patent/IL146432A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| US6727227B1 (en) | 2004-04-27 |
| EP1179008B1 (en) | 2006-03-22 |
| ATE321068T1 (en) | 2006-04-15 |
| JP3902406B2 (en) | 2007-04-04 |
| CA2373128C (en) | 2007-03-13 |
| ES2259998T3 (en) | 2006-11-01 |
| WO2000068255A2 (en) | 2000-11-16 |
| DE60026826D1 (en) | 2006-05-11 |
| IL146432A0 (en) | 2002-07-25 |
| AU2703400A (en) | 2000-11-21 |
| EP1179008A2 (en) | 2002-02-13 |
| AU769847C (en) | 2005-02-17 |
| DE60026826T2 (en) | 2007-04-12 |
| IL146432A (en) | 2007-06-03 |
| JP2003526622A (en) | 2003-09-09 |
| AU769847B2 (en) | 2004-02-05 |
| WO2000068255A3 (en) | 2001-06-14 |
| RU2157233C1 (en) | 2000-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2000068255A3 (en) | Tetrapeptide revealing geroprotective effect, pharmacological substance on its basis, and the method of its application | |
| IL149243A0 (en) | Tetrapeptide-l-alanyl-l-glutamyl-l-aspartyl-l-proline and its salts and pharmaceutical compositions containing the same | |
| HU0102272D0 (en) | Compositions and methods for stimulating gastrointestinal motilis | |
| EP1070710A3 (en) | Dithiolan derivatives, their preparation and their therapeutic effect | |
| IL140412A0 (en) | L-lys -l-glu dipeptides for pharmaceutical preparations | |
| GEP20094723B (en) | Tetraazabenzo [e] azulene derivatives and analogs thereof | |
| GB9914486D0 (en) | Medicaments | |
| JO2555B1 (en) | Oral dosage forms for propiverine or pharmaceutically acceptable salts thereof having prolonged release of the active agent | |
| CA2382919A1 (en) | Bicyclic imidazo-3-yl-amine derivatives | |
| BR0308137A (en) | Constant Release Drug Formulations Containing a Vehicle Peptide | |
| TR200101719T2 (en) | The use of apomorphine in drug manufacture for the treatment of organic erectile dysfunction in men | |
| WO2000066095A3 (en) | Use of estrone derivatives as antitumour agents | |
| CA2304135A1 (en) | Medicament formulation with a controlled release of an active agent | |
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| WO2005014032A3 (en) | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite | |
| WO2007136295A3 (en) | Peptide substance revealing a stress protective effect, pharmaceutical composition on its base and the method of its application | |
| CA2425445A1 (en) | Tetrapeptide stimulating functional activity of hepatocytes, pharmacological substance on its basis and the method of its application | |
| ATE513845T1 (en) | PEPTIDE SUBSTANCE WITH IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION BASED THEREOF AND METHOD FOR USE | |
| WO2004058303A3 (en) | Compositions of benzoquinolizine carboxylic acid antibiotic drugs | |
| CA2382654A1 (en) | Novel a-500359 derivatives | |
| WO2001017955A3 (en) | Hydroxyacetamidobenzenesulphonamide derivatives | |
| AU2002351536A1 (en) | Analogs of human growth hormone-releasing hormone, their preparation and use | |
| MXPA02006034A (en) | Oral mucosal dosage forms of apomorphine. | |
| CA2459719A1 (en) | Pharmaceutical composition comprising gamma-butyrobetaine | |
| CA2217417A1 (en) | 9-n-ethenyl derivatives of 9(s)-erythromycylamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170120 |